Beijing, China:
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) will host a seminar at the BioJapan2022 Conference on Friday, October 14. The seminar, consisting of three modules, will introduce:
- Five RenMiceTM-based totally human antibody discovery platforms: RenMabTM-based monoclonal antibody platform, RenLite®-based bispecific antibody and bispecific ADC platforms, TCR-mimic platform, and GPCR platform
- Progress of Project Integrum, a large-scale undertaking to develop antibody therapeutics for 1000+ targets by deploying in vivo evidence-based high-throughput screening
- Leading bispecific ADC belongings focusing on HER2 x TROP2 (YH012) and EGFR x c-MET (YH013)
- Phase I outcomes of YH003, an agonistic CD40 monoclonal antibody in an ongoing part II multi-regional medical trial in unresectable/metastatic PDAC sufferers
The seminar will start with an summary of Biocytogen’s therapeutic antibody discovery expertise platforms and preclinical/medical belongings supplied by Dr. Vivian Tian, together with YH003, TNFR2, B7H3, CCR8, Siglec-15, and CTLA-4 x OX40 bispecific antibody (YH006). Dr. Jie Xiang will define the corporate’s Project Integrum and antibody discovery capabilities at Biocytogen, together with modern animal fashions and preclinical pharmacology platform. Finally, Dr. Yanan Guo will introduce the corporate’s RenLite® mouse and bispecific ADC platform.
Biocytogen’s business growth staff will attend the convention and arrange a sales space (B-45). Please click on to reserve a 1-on-1 partnering assembly with us. We look ahead to seeing you on web site or on-line! Any questions, please contact us at [email protected].
About Biocytogen
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a world biotechnology firm that drives the analysis and growth of novel antibody-based medication with modern applied sciences. Using its proprietary RenMabTM /RenLite® mice platforms for totally human monoclonal and bispecific antibody growth, Biocytogen has built-in its in vivo drug efficacy screening platforms and robust medical growth experience to streamline all the drug growth course of. Biocytogen is enterprise a large-scale undertaking to develop antibody medication for greater than 1000 targets, often called Project Integrum, and has entered ongoing collaborations with dozens of companions worldwide to produce a wide range of first-in-class and/or best-in-class antibody medication. The firm’s pipeline contains 12 core belongings amongst which two are in part II multi-regional medical trials and two are in part I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For extra info, please go to http://en.biocytogen.com.cn.
View supply model on businesswire.com: https://www.businesswire.com/news/home/20220928005077/en/
